Atossa Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ATOS research report →
Companywww.atossatherapeutics.com
Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.
- CEO
- Steven C. Quay
- IPO
- 2012
- Employees
- 15
- HQ
- Seattle, WA, US
Price Chart
Valuation
- Market Cap
- $41.81M
- P/E
- -1.11
- P/S
- 0.00
- P/B
- 1.37
- EV/EBITDA
- -0.26
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -84.91%
- ROIC
- -129.89%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-34,770,000 · -36.33%
- EPS
- $-4.04 · -34.67%
- Op Income
- $-37,141,000
- FCF YoY
- -41.50%
Performance & Tape
- 52W High
- $19.35
- 52W Low
- $3.76
- 50D MA
- $5.30
- 200D MA
- $9.35
- Beta
- 1.25
- Avg Volume
- 70.01K
Get TickerSpark's AI analysis on ATOS
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 12, 26 | Steinhart Richard I | other | 10,000 |
| May 12, 26 | Chen Shu-Chih | other | 10,000 |
| May 12, 26 | Remmel H. Lawrence | other | 10,000 |
| May 12, 26 | Finn Jonathan | other | 10,000 |
| May 12, 26 | Galli Stephen J | other | 10,000 |
| May 12, 26 | Cigler Tessa | other | 10,000 |
| Mar 27, 26 | QUAY STEVEN C | other | 65,000 |
| Mar 26, 26 | Daniel Mark James | other | 63,000 |
| Jan 20, 26 | QUAY STEVEN C | other | 331,674 |
| Jan 20, 26 | QUAY STEVEN C | other | 950,000 |
Our ATOS Coverage
We haven't published any research on ATOS yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ATOS Report →